[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335268-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335268-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-experiences-of-patients-with-oesophageal-cancer-receiving-chemoradiotherapy-treatment-a-qualitative-study-embedded-in-the-scope2-trial-key-findings","The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment - a qualitative study embedded in the SCOPE2 trial - key findings","","This qualitative study explored patients’ lived experiences and perceptions within the SCOPE2 trial, which investigated radiotherapy dose escalation for locally advanced, non-metastatic oesophageal cancer. Participants were invited to longitudinal semistructured interviews across multiple time points before treatment and up to 6 months or more afterward, with data analysed thematically. Findings showed that patients experienced short- and longer-term side-effects such as nausea, throat pain, eating difficulties, fatigue, and other treatment-related issues. Most symptoms improved gradually over time, but participants needed ongoing, timely information and practical support to better manage side-effects and cancer status and sustain quality of life. Best practice involved key contacts providing advice and signposting support.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-experiences-of-patients-with-oesophageal-cancer-receiving-chemoradiotherapy-treatment-a-qualitative-study-embedded-in-the-scope2-trial-key-findings/335268/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-experiences-of-patients-with-oesophageal-cancer-receiving-chemoradiotherapy-treatment-a-qualitative-study-embedded-in-the-scope2-trial-key-findings/335268.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What did the study aim to understand about SCOPE2 participants?","Question",{"text":63,"@type":64},"It explored patients’ experiences and perceptions of the SCOPE2 trial and how chemoradiotherapy affected outlook and quality of life. It also considered the impact of the COVID-19 pandemic on those experiences.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants interviewed and at what times?",{"text":68,"@type":64},"Participants self-selected to take part in up to three semistructured longitudinal interviews across four time points: baseline (before treatment) and at 2–3 months, 3–6 months, or 6 months+ after baseline.",{"name":70,"@type":61,"acceptedAnswer":71},"What treatment-related side-effects did patients report and what happened over time?",{"text":72,"@type":64},"Patients reported side-effects including nausea, throat pain, difficulties eating and regaining appetite, thrombosis, and fatigue. Most symptoms gradually improved, though the need for ongoing information and support persisted.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335268,1790317216,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Original research  \n The experiences of patients with  \noesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial  \nDaniella Holland-Hart  ,1 Mirella Longo  ,2 Sarah Bridges  ,2 Lisette Sheena Nixon  ,2 Maria Hawkins  ,3,4 Tom Crosby,5 Annmarie Nelson  2  \nTo cite: Holland-Hart D, Longo M, Bridges S, et al. The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. BMJ Open 2024;14:e076394 . doi:10 . 1136/ bmjopen-2023-076394  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2023-076394](bmjopen-2023-076394)) .  \nReceived 06 June 2023 Accepted 21 August 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Division of Population Medicine, Cardiff University, Cardiff, UK 2Cardiff University, Cardiff, UK 3Medical Physics and Biomedical Engineering, University College London, London, UK  \n4University College London 5Velindre University NHS Trust, Cardiff, UK  \nCorrespondence to  \nDr Daniella Holland-Hart; [Holland-HartD@Cardiff.ac.uk](Holland-HartD@Cardiff.ac.uk)  \nABSTRACT  \nObjectives This qualitative study explored patients’experiences and perceptions of the SCOPE2 trial. SCOPE2 examined radiotherapy dose escalation in patients withinoperable oesophageal cancer treated with definitive chemoradiotherapy (dCRT) .  \nSetting Recruitment at five clinical sites in England and Wales, UK.  \nParticipants SCOPE2 trial participants were invited to take part in interviews from across five clinical sites. Participants self-selected to take part in up to three interviews across four different time points: baseline (before treatment) and at 2–3 months, 3–6 months or 6 months+ after baseline. There were five female and five male interview participants.  \nInterventions Participants were randomised to standard dose dCRT prescribed carboplatin/paclitaxel or cisplatin/ capecitabine, or an escalated dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine.  \nMethods This qualitative study used semistructured longitudinal interviews to explore the impact of treatment on patient outlook and quality of life and the impact of the COVID-19 pandemic. Interview data were thematically analysed.  \nResults 10 patients participated in 16 longitudinal interviews. Three participants were accompanied by companions. Participants experienced side-effects from radiotherapy and chemotherapy including nausea, throat pain, difficulties eating and regaining appetite, thrombosis and fatigue, although most of these symptoms gradually improved. Participants required more ongoing information and support regarding treatment side-effects and cancer status in order to improve their overall quality of life.  \nBest practice examples involved key contacts providing practical advice and signposting support.  \nConclusion Participants of the SCOPE2 trial  \nreported short and longer-term side-effects from chemoradiotherapy, but these usually lessened over time. Participants attempted to be positive about their survival prospects by readjusting their expectations, priorities and lifestyles. Providing patients with ongoing opportunities to discuss detailed and timely information regarding  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ This study highlighted patients’ ongoing trial and treatment experiences and the opportunity to inform trial conduct through longitudinal interviews.  \n⇒ Semistructured interviews provided rich data regarding patient experience before and during the COVID-19 pandemic, across different time points from participants across a range of age groups and genders.  \n⇒ Recruitment to this qualitative study was slow and the","cbCaiatTXjiZnKEO","https://ap.wps.com/l/cbCaiatTXjiZnKEO","pdf",442672,"English","# Abstract\n## Objectives\n## Setting and participants\n## Interventions and methods\n## Results\n## Conclusion\n# Background\n## Disease context and rationale for dCRT\n## SCOPE1 and SCOPE2 trial overview","[{\"question\":\"What did the study aim to understand about SCOPE2 participants?\",\"answer\":\"It explored patients’ experiences and perceptions of the SCOPE2 trial and how chemoradiotherapy affected outlook and quality of life. It also considered the impact of the COVID-19 pandemic on those experiences.\"},{\"question\":\"How were participants interviewed and at what times?\",\"answer\":\"Participants self-selected to take part in up to three semistructured longitudinal interviews across four time points: baseline (before treatment) and at 2–3 months, 3–6 months, or 6 months+ after baseline.\"},{\"question\":\"What treatment-related side-effects did patients report and what happened over time?\",\"answer\":\"Patients reported side-effects including nausea, throat pain, difficulties eating and regaining appetite, thrombosis, and fatigue. Most symptoms gradually improved, though the need for ongoing information and support persisted.\"}]","The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment - a qualitative study embedded in the SCOPE2 trial - key findings | PDF",1790010345,25]